|
マツモト エツコ
Matsumoto Etsuko
松本 悦子 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma. |
| 掲載誌名 | 正式名：Asia Pacific allergy 略 称：Asia Pac Allergy ISSNコード：22338276/22338276 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 11(3),pp.e31 |
| 著者・共著者 | Kobayashi Konomi†, Nagase Hiroyuki, Sugimoto Naoya, Yamamoto Shiho, Tanaka Akihiko, Fukunaga Koichi, Atsuta Ryo, Tagaya Etsuko, Hojo Masayuki, Gon Yasuhiro, |
| 発行年月 | 2021/07 |
| 概要 | Background:Mepolizumab, a humanized antibody targeting interleukin-5, decreases the number of blood eosinophils and the frequency of exacerbation of severe asthma. Galectin-10 is a protein within the cytoplasm of eosinophils and constitutes Charcot-Leyden crystals, which promotes key features of asthma. However, the relationship between time kinetics and clinical response of eosinophil-derived molecules such as galectin-10 or eosinophil cationic protein (ECP) has not been precisely investigated.Objective:This study aimed to clarify the precise time course of the levels of serum galectin-10 and ECP after mepolizumab treatment and to analyze the relationship between the levels of eosinophil-derived molecules and the clinical background or response to mepolizumab treatment.Methods:This multicenter, prospective open-label study recruited 20 patients with severe eosinophilic asthma. Mepolizumab was administered every 4 weeks for 32 weeks and the levels of various biomarkers were serially analyzed.Results:The serum galectin-10 and ECP significantly and rapidly decreased 4 weeks after initial administration of mepolizumab. In contrast, basophil count, fractional exhaled nitric oxide, and the serum total IgE level were unchanged during treatment. Asthma Control Questionnaire-5, Asthma Health Questionnaire-33, and Lund-Mackay scores significantly improved after mepolizumab treatment. Both high ECP and eosinophil count related to better response in forced expiratory volume in 1 second (FEV1) and measurable ECP level at 4 weeks after administration of mepolizumab related to the further improvement in FEV1 toward week 32. No significant difference in improvement in FEV1 was observed in galectin-10 high group. The level of ECP at baseline was significantly related to the higher prevalence of nasal polyp and Lund-Mackay score.Conclusion:This study was the first to show that the levels of serum galectin-10 decreases after initial administration of mepolizumab. The significant rela |
| DOI | 10.5415/apallergy.2021.11.e31 |
| PMID | 34386407 |